Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Status of Malaria Vaccine Introduction-Africa, 2019-2024.

Created on 18 Sep 2026

Authors

Anh N Ly, Jenny A Walldorf, Mary J Hamel, Eliane Pellaux-Furrer, Rafiq Nii Attoh Okine, Mgaywa G M D Magafu, Jaymin C Patel, Terri B Hyde

Published in

The American journal of tropical medicine and hygiene. Sep 17, 2026. Epub Sep 17, 2026.

Abstract

Malaria remains the primary cause of death among children younger than 5 years old in Africa. During 2019-2023, Ghana, Kenya, and Malawi piloted introduction of the first malaria vaccine, RTS,S/AS01, through the Malaria Vaccine Implementation Program. There are two malaria vaccines prequalified by the WHO: RTS,S/AS01 and R21/Matrix-M. The vaccines are recommended for children younger than 5 years old in endemic areas, prioritizing areas of moderate to high transmission. Data on vaccine introduction and doses shipped were obtained from the WHO and the United Nations Children's Fund. As of December 2024, 17 countries in Africa had introduced the malaria vaccine with support from Gavi, the Vaccine Alliance, and another eight countries had approval for Gavi support. During 2023-2024, a total of 13,250,098 vaccine doses were shipped to countries. The introduction of the malaria vaccine presents an integration opportunity with preventive health services to reduce child morbidity and mortality.

PMID:
42753714
Bibliographic data and abstract were imported from PubMed on 18 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement